The DCPS Knockout HEK293 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the gene encoding scavenger decapping enzyme (DCPS) has been disrupted via targeted genome editing in the HEK293 host cell line. This polyclonal population comprises a heterogeneous mixture of cells carrying various loss-of-function modifications at the DCPS locus, providing a robust model for studying the consequences of DCPS deficiency without clonal selection artifacts. The knockout model is designed for functional investigations of mRNA decapping, RNA turnover, and pre-mRNA splicing processes.
HEK293 cells, originally derived from human embryonic kidney tissue, exhibit an adherent, epithelial-like morphology and are widely employed in biomedical research for recombinant protein expression, viral particle production, and transient transfection studies. Their ease of manipulation and high transfection efficiency make them a preferred chassis for CRISPR-based genome engineering. The epithelial origin and stable karyotype (though aneuploid) provide a consistent background for studying gene function, particularly in RNA metabolism pathways that are active in this cell type.
DCPS is a critical component of the mRNA decay machinery, hydrolyzing the m7G cap from capped oligonucleotides produced by 3??-to-5?? exonucleolytic degradation. It functions downstream of DCP2 and XRN1, scavenging residual cap structures. DCPS interacts with decapping co-activators DCP1A and DCP1B and associates with the LSM complex and EDC3, integrating its activity with mRNA surveillance and degradation networks. These interactions modulate the stability of capped RNA fragments and influence pre-mRNA splicing, coupling RNA decay to gene expression quality control.
In the HEK293 background, disruption of DCPS impairs the clearance of m7G-capped decay intermediates, leading to altered mRNA stability and potential perturbations in splicing fidelity. This polyclonal knockout cell population serves as a physiologically relevant model to dissect the roles of DCPS in RNA metabolism without the confounding effects of clonal variation. It enables the study of DCPS-dependent regulation of gene expression in a human epithelial context, a setting pertinent to diseases such as alopecia, neurological defects, and endocrinopathy syndrome (ANES) as well as certain cancers where DCPS is implicated.
Researchers can utilize these DCPS knockout polyclonal HEK293 cells for a variety of advanced applications, including in vitro decapping assays to directly measure enzymatic activity, RNA stability assays to assess transcript half-life changes, RT-qPCR profiling of endogenous mRNA targets, western blotting for DCPS protein verification, and immunofluorescence to examine subcellular distribution of RNA decay factors. They are particularly valuable for evaluating DCPS inhibitors as potential cancer therapeutics and for modeling the molecular pathology of neurological disorders linked to RNA metabolism defects. For further technical details and ordering information, please contact Ascent Research.
